Effects of Angiotensin II Type 1 Receptor Blockade on the Systemic Blood Nitric Oxide Dynamics in N.OMEGA.-Nitro-L-Arginine Methyl Ester-Treated Rats

Kanematsu, Yasuhisa; Tsuchiya, Koichiro; Ohnishi, Hideki; Motobayashi, Yuki; Izawa, Yuki; Ishihara, Manabu; Ishizawa, Keisuke; Abe, Shinji; Kawazoe, Kazuyoshi; Takahashi, Toshiaki

doi:10.1291/hypres.29.369

Cited by 19 publications

(6 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At the starting point of the experiment, basal systolic blood pressure (SBP) was up to 105 mmHg, and there were no significant differences among groups. L-NAME treatment caused a progressive increase in SBP from the first week, reaching the value of 146 ± 7 mmHg at week 3, which was consistent with our previous findings (33). Co-administration of nitrosonifedipine tended to decrease the SBP, although no significant difference was observed in SBP between the L-NAME-treated group and L-NAME + nitrosonifedipine group because of the weak L-type Ca…”

Section: Name-induced Hypertensive Ratssupporting

confidence: 91%

See 1 more Smart Citation

Drug Discovery for Overcoming Chronic Kidney Disease (CKD): Development of Drugs on Endothelial Cell Protection for Overcoming CKD

et al. 2009

Self Cite

View full text Add to dashboard Cite

Abstract. Chronic kidney disease (CKD) is becoming a major public health problem worldwide. It is important to protect endothelial function in CKD treatment because injury of the endothelium is a critical event for the generation and progression of CKD. Recently, clinical studies showed that nifedipine, an antihypertensive drug, acts as a protective agent of endothelial cells (ECs). Nifedipine is reported to partially decompose to a nitrosonifedipine that has high reactivity against lipid-derived radicals in vitro. However, it is still unclear whether nitrosonifedipine is a biologically active agent against endothelial injury. We observed that nitrosonifedipine was converted to radical form by reaction with cultured ECs. The cumene hydroperoxide mediated cytotoxity was reduced by nitrosonifedipine in cultured human glomerular ECs (HGECs). Also nitrosonifedipine suppressed the expression of TNF-α-induced intercellular cell adhesion molecule-1 in HGECs. Chronic administration of N ω -nitro-L-arginine methyl ester (L-NAME) caused systemic arterial hypertension, endotherial injury, and renal dysfunction. In L-NAMEinduced hypertensive rats, nitrosonifedipine treatment improved not only the acetylcholineinduced vasodilation of the aortic rings, but also renal dysfunction such as increasing the levels of serum creatinine and urinary protein excretion. Our preliminary data suggest that nitrosonifedipine is a new and useful drug for the treatment of CKD involving ameliorating effects on EC disorder.

show abstract

Section: Name-induced Hypertensive Ratssupporting

confidence: 91%

“…L-NAME (1 g / l) was administered in drinking water for three weeks. Daily intake of L-NAME was estimated to be 20 -30 mg per rat (33). At the starting point of the experiment, basal systolic blood pressure (SBP) was up to 105 mmHg, and there were no significant differences among groups.…”

Section: Name-induced Hypertensive Ratsmentioning

confidence: 99%

Drug Discovery for Overcoming Chronic Kidney Disease (CKD): Development of Drugs on Endothelial Cell Protection for Overcoming CKD

et al. 2009

Self Cite

View full text Add to dashboard Cite

show abstract

“…It was recently reported that ACE inhibitors or AT1 receptor blockers increase blood levels of NO, the antiproliferative effects of which can combine with the absence of proliferative effects of angiotensin II via AT1 receptors (34).…”

Section: Fig 4 the Relationships Between Basal Map And Captopril-inmentioning

confidence: 99%

Antihypertensive Mechanisms of Chronic Captopril or N-Acetylcysteine Treatment in L-NAME Hypertensive Rats

2006

View full text Add to dashboard Cite

show abstract

“…NOS inhibitors such as l ‐NAME are generally used in hypertensive animal models. Examination on new drug targets has been performed to provide well‐tolerated treatments . Antihypertensive properties of diverse foods and natural products have been pointed .…”

Section: Discussionmentioning

confidence: 99%

Propolis reduces oxidative stress in l‐NAME‐induced hypertension rats

Talas

2013

Cell Biochemistry & Function

View full text Add to dashboard Cite

The inhibition in the synthesis or bioavailability of nitric oxide (NO) has an important role in progress of hypertension. The blocking of nitric oxide synthase activity may cause vasoconstriction with the formation of reactive oxygen species (ROS). Propolis is a resinous substance collected by honey bees from various plants. Propolis has biological and pharmacological properties. The aim of this study was to examine the effect of propolis on catalase (CAT) activity, malondialdehyde (MDA) and NO levels in the testis tissues of hypertensive rats by Nω-nitro-l-arginine methyl ester (l-NAME). Rats have received nitric oxide synthase inhibitor (l-NAME, 40 mg kg(-1) , intraperitoneally) for 15 days to produce hypertension and propolis (200 mg kg(-1) , by gavage) during the last 5 days. MDA level in l-NAME-treated group significantly increased compared with control group (P < 0.01). MDA level of l-NAME + propolis-treated rats significantly reduced (P < 0.01) compared with l-NAME-treated group. CAT activity and NO level significantly reduced (P < 0.01) in l-NAME group compared with control group. There were no statistically significant increases in the CAT activity and NO level of the l-NAME + propolis group compared with the l-NAME-treated group (P > 0.01). These results suggest that propolis changes CAT activity, NO and MDA levels in testis of l-NAME-treated animals, and so it may modulate the antioxidant system.

show abstract

Effects of Angiotensin II Type 1 Receptor Blockade on the Systemic Blood Nitric Oxide Dynamics in N.OMEGA.-Nitro-L-Arginine Methyl Ester-Treated Rats

Cited by 19 publications

References 33 publications

Drug Discovery for Overcoming Chronic Kidney Disease (CKD): Development of Drugs on Endothelial Cell Protection for Overcoming CKD

Drug Discovery for Overcoming Chronic Kidney Disease (CKD): Development of Drugs on Endothelial Cell Protection for Overcoming CKD

Antihypertensive Mechanisms of Chronic Captopril or N-Acetylcysteine Treatment in L-NAME Hypertensive Rats

Propolis reduces oxidative stress in l‐NAME‐induced hypertension rats

Contact Info

Product

Resources

About